Migraine
Biohaven Announces NURTEC® ODT Receives First Global Approval Outside the U.S. For Prevention of Migraine
Biohaven
PR-M12-21-01Dec 13, 2021
Pharma Marketing
Biohaven Recruits Khloe Kardashian for Migraine Campaign
Biohaven
PR-M07-20-NI-025Jul 16, 2020
Biohaven to Advance Vazegepant Into Phase 3 for Acute Migraine Treatment
Biohaven
PA1632Mar 27, 2020
Clinical Results
Biohaven Achieves Positive Topline Results for Intranasal Migraine Treatment
Biohaven
PR-M12-19-NI-025Dec 17, 2019
Investment
Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
Biohaven
PR-M12-18-NI-084Dec 28, 2018
Public Offering
Biohaven Announces Proposed Public Offering of Common Shares
Biohaven
PR-M12-18-NI-060Dec 18, 2018
Clinical Results
Biohaven Reports Positive Results From Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety
Biohaven
PR-M09-18-NI-060Sep 20, 2018
Bioequivalence Study
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet
Biohaven
PR-M01-18-NI-034Jan 12, 2018